MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
NanoViricides Net Income 2011-2026 | NNVC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income NanoViricides
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.47 M | -8.29 M | -8.59 M | -8.11 M | -8.82 M | -13.4 M | -8.42 M | -8.56 M | -10.3 M | -10.7 M | -2.2 M | -14.1 M | -8.88 M | -6.21 M | -6.48 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.2 M | -14.1 M | -8.84 M |
Quarterly Net Income NanoViricides
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.22 M | -1.79 M | - | -2.22 M | -2.03 M | -3.13 M | - | -1.85 M | -2.11 M | -1.97 M | - | -1.7 M | -1.75 M | -1.57 M | -3.32 M | -1.79 M | -1.92 M | -2.61 M | -4.53 M | -2.11 M | -2.33 M | -2.33 M | -2.33 M | -2.31 M | -1.93 M | -1.93 M | -1.93 M | -1.56 M | -2.23 M | -2.23 M | -2.23 M | -1.84 M | -2.8 M | -2.01 M | -2.8 M | -2.01 M | -1.55 M | -3.06 M | -1.55 M | -3.06 M | -2.78 M | -1.31 M | -2.78 M | -1.31 M | -1.88 M | 852 K | -1.88 M | 852 K | -1.36 M | -6.56 M | -1.69 M | -6.27 M | -1.21 M | -1.8 M | -1.21 M | -1.8 M | -1.39 M | -1.14 M | -1.39 M | -1.14 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 852 K | -6.56 M | -2.1 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Exelixis
EXEL
|
783 M | $ 48.43 | 9.03 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
6.82 M | $ 2.56 | 3.96 % | $ 71.4 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Galapagos NV
GLPG
|
-103 M | $ 28.78 | 1.36 % | $ 2.69 B |  Belgium |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | France |
 |
Genmab A/S
GMAB
|
4.76 B | $ 27.93 | 1.41 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
-16.2 M | $ 0.9 | 2.02 % | $ 839 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Grifols, S.A.
GRFS
|
265 M | $ 8.41 | 1.69 % | $ 6.83 B |  Spain |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
InflaRx N.V.
IFRX
|
-45.6 M | $ 2.47 | 25.39 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-229 M | $ 76.96 | 2.27 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
-2.23 M | $ 8.3 | 1.1 % | $ 260 M |  Israel |
 |
BioNTech SE
BNTX
|
10.3 B | $ 95.07 | -0.45 % | $ 27.2 B | Germany |
 |
Kymera Therapeutics
KYMR
|
-311 M | $ 86.14 | 4.15 % | $ 7.28 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-4.03 M | $ 229.83 | -1.06 % | $ 4.2 B | USA |
 |
INmune Bio
INMB
|
-45.9 M | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
-68.9 M | $ 41.84 | 4.26 % | $ 3.6 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-23.4 M | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
226 M | $ 22.32 | -0.13 % | $ 3.7 B | USA |
 |
MannKind Corporation
MNKD
|
5.86 M | $ 3.68 | 28.5 % | $ 1.12 B | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-47 M | $ 42.28 | 21.6 % | $ 286 B | France |
 |
Esperion Therapeutics
ESPR
|
-22.7 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 3.47 | -8.44 % | $ 5.71 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 23.86 | 1.88 % | $ 3.04 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Puma Biotechnology
PBYI
|
31.1 M | $ 7.5 | 2.04 % | $ 375 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |